JAMA vs BMJ Open: Which Journal Should You Choose?

JAMA asks whether the paper is important enough to command the attention of medicine broadly. BMJ Open asks whether the paper is trustworthy, complete, and medically relevant enough to justify transparent publication in a soundness-first journal.

That's a deep difference.

At JAMA, a paper can fail because the result isn't broad enough in consequence. At BMJ Open, a paper can fail because the question is vague, the methods package is incomplete, the reporting is thin, or the conclusions outrun the design.

JAMA wins when the paper reads like a broad clinical event.

That usually means:

• a result with immediate practice consequences across specialties
• comparative-effectiveness, health-services, or policy work with broad reach
• a paper whose clinical relevance is obvious to non-specialists
• a manuscript that becomes stronger when written for all of medicine rather than a narrower audience

JAMA's editorial guidance are very clear on this. Editors aren't looking for a good paper that wants a bigger logo. They're looking for a paper that truly belongs in a broad medical conversation.

BMJ Open wins when the study is worth publishing because it's rigorous, useful, and transparently reported, even if it isn't a flagship event.

That includes:

• observational studies
• protocols
• negative results
• implementation and health-services studies
• epidemiology and public-health work
• medically relevant studies that benefit from open access and transparent review

BMJ Open's editorial guidance are especially good on this point. The journal is broad on study type, but demanding on reporting discipline.

That matters because many solid studies aren't built around a dramatic positive finding. BMJ Open can still be the right home when the contribution comes from transparency, careful design, and usable evidence.

BMJ Open fit's editorial guidance emphasizes that peer-review files are published for accepted manuscripts. That changes the editorial psychology. Authors should expect more scrutiny of the reporting package, because reviewers and readers can later see how the manuscript evolved.

A perfectly reported observational study can still be a weak JAMA submission if the implication is too modest for a flagship general-medical venue. Reporting quality is necessary there, but not sufficient.

BMJ Open submission's editorial guidance is explicit that protocols, checklists, declarations, and supplementary materials are part of the editorial signal. Authors who treat them as upload admin often weaken the paper before review.

• the paper has broad clinical or policy consequences across medicine
• the result could influence practice or systems thinking outside one niche
• the manuscript is strong enough to survive a flagship priority filter
• the paper gets stronger when generalized for a broad physician audience

That's a narrow lane.

• the paper is methodologically sound and medically relevant
• the main strength is rigor, transparency, and usefulness
• the design is observational, protocol-based, implementation-focused, or not obviously flagship in consequence
• open access and broad discoverability are strategic advantages
• the manuscript would be weakened by pretending it's bigger than the data allow

That's a much wider and often more honest lane.

This is a practical cascade.

If JAMA rejects the paper because it's too narrow, too observational, or too modest in immediate consequence, BMJ Open can be a sensible next move.

That works best when:

• the study question is still important
• the reporting package is strong
• the design is clean and transparent
• the conclusions have already been tightened to match the evidence

It works less well when the manuscript is still underreported or is using broad language to hide design weakness. BMJ Open isn't a rescue venue for sloppy packaging.

The flagship problem is often not that the science is bad. It's that the paper doesn't feel important enough across medicine to justify one of the journal's limited slots.

source's editorial guidance say this repeatedly. Papers get into trouble when the study question is fuzzy, sample construction is hard to reconstruct, checklists are incomplete, or the discussion overstates what the design can support.

If the title, abstract, and early results don't make the broad consequence visible quickly, editors lose confidence fast.

The journal's broad remit doesn't mean loose editorial standards. It means a different kind of discipline, focused on transparency and soundness rather than maximal novelty.

These are straightforward BMJ Open candidates. They aren't natural JAMA submissions.

Negative results with strong design can be very appropriate at BMJ Open. JAMA can publish null results, but only when the consequence is unusually broad and definitive.

These can go either way, but many are cleaner BMJ Open papers unless they clearly change broad policy or clinical practice.

If the paper is large, generalizable, and genuinely broad in consequence, JAMA can be realistic. If the real value is careful inference, transparent reporting, and medical utility, BMJ Open is usually the cleaner home.

A strong JAMA first page usually declares a result that feels immediately consequential to medicine broadly. The manuscript should tell editors quickly why the paper matters now.

A strong BMJ Open first page does something different. It makes the question, design, population, and limitation profile easy to trust. The paper looks operationally honest and publication-ready.

That distinction catches a surprising number of targeting mistakes.

Ask what sentence best describes the paper:

• "this changes how medicine or policy should think now" points toward JAMA
• "this is a solid and useful medical study that deserves visible, transparent publication" points toward BMJ Open

That sentence often exposes overreach faster than any metrics table.

For many teams, BMJ Open is the more strategic choice because it aligns the journal with the manuscript's actual strengths. That often means:

• better fit for observational or implementation work
• stronger open-access visibility
• lower risk of prestige overreach
• a review culture that rewards transparency instead of rhetorical scale

This is especially true when the paper matters, but will never honestly read like a JAMA-level clinical event.

Send to JAMA first if:

1. the paper has broad cross-specialty clinical or policy consequence
2. the result could change practice or systems thinking immediately
3. the manuscript reads like a flagship general-medical paper without needing hype

Send to BMJ Open first if:

1. the paper is strongest on rigor and usefulness
2. the study design is solid, but the consequence isn't flagship-scale
3. transparency, open access, or protocols and negative results are part of the value
4. the package is reporting-complete and operationally clean